PNC Financial Services Group
GLUE icon

PNC Financial Services Group’s Monte Rosa Therapeutics GLUE Stock Holding History

PNC Financial Services Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.52K Hold
457
– – ﹤0.01% 4077
2025
Q4 		$7.17K Hold
457
– – ﹤0.01% 4090
2025
Q3 		$3.39K Buy
457
+340
+291% +$1.8K ﹤0.01% 4347
2025
Q2 		$528 Buy
117
+51
+77% +$227 ﹤0.01% 4679
2025
Q1 		$306 Buy
66
+38
+136% +$233 ﹤0.01% 4723
2024
Q4 		$194 Hold
28
– – ﹤0.01% 4654
2024
Q3 		$148 Hold
28
– – ﹤0.01% 4701
2024
Q2 		$105 Buy
+28
New +$143 ﹤0.01% 4714

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

PNC Financial Services Group's GLUE Position: Q1 2026 in Review

PNC Financial Services Group held its Monte Rosa Therapeutics (GLUE) position steady in Q1 2026 at 457 shares worth $7.52K. The position accounts for ﹤0.01% of the portfolio, ranked #4077.

PNC Financial Services Group first reported a position in GLUE in Q2 2024 and has held it in 8 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • PNC Financial Services Group held 457 shares of Monte Rosa Therapeutics worth $7.52K as of Q1 2026.
  • PNC Financial Services Group left its Monte Rosa Therapeutics share count unchanged in Q1 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4077 holding.
  • PNC Financial Services Group first reported a position in Monte Rosa Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.